Elser Financial Planning Inc Has $876,000 Stock Holdings in Novo Nordisk A/S $NVO

Key Points

• Elser Financial Planning Inc has increased its stake in Novo Nordisk A/S by 241.7% in the second quarter, bringing its holdings to $876,000 in value.
• Several institutional investors have also significantly increased their positions in Novo Nordisk A/S, with GAMMA Investing LLC raising its stake by an impressive 7,508.7%.
• Research analysts have mixed opinions on Novo Nordisk A/S, with a consensus rating of "Hold" and a price target around $75.33.

Elser Financial Planning Inc increased its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 241.7% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,692 shares of the company's stock after purchasing an additional 8,978 shares during the quarter. Elser Financial Planning Inc's holdings in Novo Nordisk A/S were worth $876,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of NVO. Revolve Wealth Partners LLC raised its position in Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after purchasing an additional 200 shares during the last quarter. Moody National Bank Trust Division acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at $224,000. AdvisorNet Financial Inc raised its position in shares of Novo Nordisk A/S by 34.0% during the first quarter. AdvisorNet Financial Inc now owns 3,741 shares of the company's stock worth $260,000 after acquiring an additional 950 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Novo Nordisk A/S by 7,508.7% during the first quarter. GAMMA Investing LLC now owns 657,319 shares of the company's stock valued at $45,644,000 after acquiring an additional 648,680 shares during the period. Finally, BTC Capital Management Inc. boosted its holdings in Novo Nordisk A/S by 3.2% in the first quarter. BTC Capital Management Inc. now owns 10,958 shares of the company's stock valued at $761,000 after acquiring an additional 344 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

NVO has been the subject of several recent research reports. Wall Street Zen cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. TD Cowen lowered their price target on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating for the company in a research report on Tuesday, August 19th. BNP Paribas upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a report on Wednesday, August 13th. BNP Paribas Exane raised shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price objective on the stock in a research note on Wednesday, August 13th. Finally, HSBC cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 target price for the company. in a research report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of "Hold" and a consensus price target of $75.33.

Novo Nordisk A/S Trading Down 0.8%

NYSE NVO opened at $55.61 on Monday. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $121.34. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The firm has a market cap of $248.30 billion, a P/E ratio of 15.28, a P/E/G ratio of 2.11 and a beta of 0.66. The stock's 50-day moving average is $56.03 and its 200-day moving average is $64.38.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.04. The business had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were issued a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.